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Abstract 

Background: A urinary biomarker panel including alpha-1-acid-glycoprotein (AGP), lipocalin-like-prostaglandin-D-synthase (LPGDS), transferrin and ceruloplasmin demonstrates an ‘excellent’ ability for identifying active lupus nephritis (LN) in UK/US children. This study aimed to assess if this panel identifies active LN within the South African (SA) Paediatric Lupus Cohort. Methods: Juvenile-onset-systemic lupus erythematosus (JSLE) patients aged <19 years at diagnosis, and healthy controls (HCs) recruited. Patients categorised as having active LN (renal BILAG score; A/B and previous histological confirmation) or inactive LN (renal BILAG score: D/E). Urinary biomarkers quantified by ELISA. Mann Whitney-U-test compared biomarker levels between groups. Binary logistic regression and receiver operating curve analysis assessed biomarker combinations. Results: Twenty-three JSLE patients recruited with a median age of 13.5 years [IQR 12.7-14.9] and disease duration of 2.6 years [IQR 1.8-4.0]. Eighteen HCs had a median age of 11.0 years [IQR 10.0-12.0]. AGP, LPGDS, transferrin, ceruloplasmin and VCAM-1 were significantly higher in active than inactive LN patients (corrected p-values, all pc<0.05), with no difference between inactive LN patients and HCs (all pc=1.0). The optimal biomarker combination included AGP, ceruloplasmin, LPGDS and transferrin (AUC=1.0). Conclusions: A urinary biomarker panel comprised of AGP, ceruloplasmin, LPGDS and transferrin previously validated within UK/US cohorts also performed excellently within a racially distinct SA Cohort which displayed more severe LN. 
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Introduction 
Juvenile-onset systemic lupus erythematosus (JSLE), also known as childhood-onset SLE, is a rare, severe multisystem autoimmune disease. Significant differences exist between JSLE and adult-onset SLE patients, with JSLE patients displaying a more aggressive course than adult onset SLE patients  ADDIN EN.CITE [1-4], including more renal involvement. Up to 80% of JSLE patients  ADDIN EN.CITE [1] develop Lupus Nephritis (LN), compared with 40-50% or adults  ADDIN EN.CITE [5, 6]. The clinical presentation of LN is very heterogeneous, ranging from asymptomatic to overt features of nephrotic and/or nephritic syndrome. LN may be part of the patients’ initial presentation or occur later in the disease course. It characteristically follows a relapsing and remitting course, requiring close surveillance and prompt treatment to prevent renal damage. 

Renal biopsy is the gold standard for diagnosing LN, characterising disease activity and predicting prognosis  ADDIN EN.CITE [7, 8]. At present, there is no international consensus as to the optimal timing of the initial renal biopsy in children. The invasive nature of biopsies and risk of complications (e.g. bleeding, infection, and need for anaesthetic in children) leads to a tendency for renal biopsies to be avoided until deemed absolutely necessary, with clinical concern that irreversible renal damage may occur in the interim  ADDIN EN.CITE [9]. The value of the renal biopsy has also been questioned more recently as a number of studies have demonstrated poor inter-observer agreement in LN class classification between pathologists   ADDIN EN.CITE [10-13].

Novel, non-invasive urinary biomarkers of LN disease activity are investigated with interest in light of these difficulties. Initially, urinary biomarker studies focused on individual urinary biomarkers which were shown to outperform both traditional and novel serum biomarkers for active LN identification  ADDIN EN.CITE [14-20]. More recently, improvement in both diagnostic and prognostic ability has been demonstrated by using combinations of urinary biomarkers  ADDIN EN.CITE [4, 21, 22]. In a study including 91 JSLE patients from the United Kingdom and United States (US) of America (61 from the UK JSLE Cohort Study; and 30 from the US Einstein Lupus Cohort), we have previously demonstrated that a combination of urinary biomarkers including alpha-1-acid-glycoprotein (AGP), ceruloplasmin (CP), lipocalin-like-prostaglandin-D synthase (LPGDS) and transferrin (TF) display an excellent ability for active LN identification (AUC of 0.920 in the UK and 0.991 in the US cohorts respectively). In this study, patients were defined as having active LN if they demonstrated a composite renal British Isles Lupus Assessment Group (BILAG) 2004 score of A or B, and had had renal biopsy defined active LN during their disease course  ADDIN EN.CITE [4]. A further study has assessed how a combination of urinary biomarkers relates to the composite National Institute for Health (NIH) histological LN activity index and the tubulo-interstitial activity index (AI and TIAI respectively) in 47 JSLE patients. The combination of neutrophil gelatinase-associated lipocalin (NGAL), MCP-1, CP, adiponectin, hematopexin and kidney injury molecule-1 (KIM-1) was found to predict NIH AI status with >92% accuracy and TIAI status with >80% accuracy  ADDIN EN.CITE [22]. 

Marked differences in JSLE, LN phenotypes and clinical outcomes have been demonstrated according to race origin. In a US study looking at the outcomes of hospitalised JSLE patients, African American patients were shown to have more hospital admissions, with both Hispanic and African American patients also demonstrating higher mortality and end stage renal failure rates  ADDIN EN.CITE [23]. In a US adult SLE study, the standardised incidence ratio of end stage LN requiring renal replacement therapy was 11.1 for African American patients, 4.9 for ‘other ethnicity’ patients and 1.7 for Caucasian patients. Amongst patients with end stage renal disease, African Americans displayed a higher mortality rate  ADDIN EN.CITE [24]. Such differences make it important that promising biomarkers are validated within different patient cohorts with a spectrum of disease severity and races.

Lewandowski et al have already demonstrated within the South African (SA) Paediatric Lupus Cohort (included within the current study and referred to as the ‘SA Cohort’), that 61% of patients presented with LN, with 63% of these patients displaying severe International Society of Nephrology and Renal Pathology Society (ISN / RPS) class III or IV LN. Compared to the North American Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Cohort  ADDIN EN.CITE [25], increased LN severity was also demonstrated, with 15% of the SA Cohort patients requiring dialysis compared to 1% in the CARRA cohort (p<0.001). Strikingly, higher renal transplantation rates were also seen within the SA cohort; 8% versus <1% in North American peers (p<0.001)  ADDIN EN.CITE [26]. Within an adult SA SLE cohort, the 5-year survival rate has been shown to be 78% [27], compared with >90% in many industrialised countries  ADDIN EN.CITE [28-31]. In a further study, SA patients with proliferative LN demonstrated lower renal survival rates than in non-African countries; with 5- and 10- year survival rates of 63% and 52% respectively  ADDIN EN.CITE [32] compared with 97% and 96% within the SLICC Inception Cohort (patients from Europe and North America)  ADDIN EN.CITE [33]. 

Assessment of the urinary biomarker panel for active LN identification, already demonstrated in UK and US JSLE cohorts as detailed above (including AGP, CP, LPGDS, TF  ADDIN EN.CITE [4]), is therefore warranted within the racially diverse SA Cohort, to assist with clinical translation of these promising urinary biomarkers. The aims of this present study are to evaluate the performance of this urinary biomarker panel cross-sectionally within the racially distinct and relatively more severe LN phenotype SA cohort  ADDIN EN.CITE [26], to see if the same ability for identification of active LN can be demonstrated. 

Methods
Patient cohort
This study was based upon the SA Paediatric Lupus Cohort which collects clinical data and urine samples from JSLE patients attending two tertiary care, government-funded university hospitals in Cape Town, SA (Red Cross War Memorial Children’s and Groote Schuur Hospitals)  ADDIN EN.CITE [26]. The study was carried out as a collaboration between the University of Cape Town (SA), the University of Liverpool (UK) and Duke University (USA). 

Participants
Eligible patients were diagnosed with JSLE prior to 19 years of age and met ≥4 of the revised ACR SLE classification criteria [34]. They were identified by searching the in-patient and out-patient computerised databases of each hospital using the International Classification of Disease version 10 codes for SLE and LN. Physicians at both hospitals were also surveyed to create a complete list of JSLE patients. Patients were excluded if they had other diseases which might explain their ACR criteria (e.g. active tuberculosis, and/or HIV), if their urine samples displayed urine dipstick signs of urinary tract infection or if no urine samples had been collected. Clinical data and samples were collected during routine clinical care and included detailed demographic data, self-reported race/ethnicity data, clinical laboratory results and medication information. HCs were also included within the study. They were identified from elective surgical lists and out-patient clinics, were <19 years of age and were screened for the absence of underlying inflammatory or connective tissue disorders or kidney diseases, using a questionnaire. 

Compliance with ethical standards
The study had full ethical approvals in place from the University of Cape Town ethics committee (HREC No. 424-2013) and was carried out in accordance with the Declaration of Helsinki. Patients were approached for written consent by their physician or the study’s research nurse. Parental consent was obtained for all patients. For patients aged 13 to 18 years old, assent was also obtained. Consent was carried out in the language preferred by the patient and family (Afrikaans, Xhosa, or English). Where the patients or family were unable to read the participant information sheet, this was read to them and explained in their preferred language by the physician or research nurse.

Renal disease activity classification
Patients were categorised according to the renal domain of BILAG2004 disease activity score, defined as follows; BILAG2004 grade A or B (severe or moderate disease respectively), grade C (mild or improving renal disease), grade D (inactive disease but previous system involvement), grade E (renal system has never been involved)  ADDIN EN.CITE [35]. The composite renal BILAG score consisted of six clinical or laboratory items, including proteinuria (defined by the urine dipstick or urine protein / albumin creatinine ratio or 24-hour protein levels), renal function deterioration (based upon plasma creatinine and glomerular filtration rate), presence of active urinary sediment, hypertension (>95th percentile for age / height / gender), nephrotic syndrome and histological evidence of active nephritis in the previous three months (ISN/RPS histological classification  ADDIN EN.CITE [36]). All active LN patients had biopsy-proven LN during their disease course. Therefore, active LN patients were defined as having a renal BILAG2004 score of A or B with previous histological confirmation of LN, whereas inactive LN had a renal BILAG2004 score of D or E. Renal BILAG2004 C were excluded as this study sought to identify biomarkers differentiating between the binary outcome of active versus inactive LN.

Urine sample processing
Random mid-stream urine samples were collected and processed as soon as possible, or kept refrigerated or on ice until processing (up to 2 hours). The urine sample processing protocol was the same as that of the previous urine biomarker panel study assessing urine biomarker combinations in UK and US JSLE Cohort patients  ADDIN EN.CITE [4]. Samples were centrifuged at 2000 rpm for 10 minutes. The urine supernatant was divided into 1ml aliquots and stored in Eppendorf tubes at -80oC, without additives, before being batch transferred on dry ice to the University of Liverpool (UK).

Laboratory techniques
The methodology used for urinary biomarker quantification were those described previously in the previous urinary biomarker panel study assessing urine biomarker combinations in UK and US JSLE Cohort patients  ADDIN EN.CITE [4]. In brief, pre-coated enzyme-linked immunosorbent assay (ELISA) kits were used for quantification of urinary CP (St Charles, Assay Pro, USA), TF (GenWay, San Diego, USA), LPGDS (BioVendor, Brno, Czech Republic), AGP and MCP-1 (R&D Systems Ltd, Minneapolis, USA). An R&D systems duo-kit (R&D Systems Ltd, Minneapolis, USA) was used to quantify urinary VCAM-1. All biomarker results were standardised for urinary creatinine (Cr) concentration and presented in units (nanogram or picogram) per milligram creatinine (mgCr).

Statistical analysis
Summary statistics for demographics, baseline clinical data, and biomarker data are presented as median values and interquartile ranges (IQRs). Mann-Whitney U, Kruskall Wallis or Chi Squared tests were used to assess for differences in demographic, clinical factors and biomarker concentrations between different patient groups as appropriate. Due to the number of factors explored, a Bonferroni adjustment was applied to account for multiple testing (20 comparisons between active and inactive LN patients, four comparisons between active, inactive and HCs, and six comparisons between inactive and HCs, threshold for significance pc<0.05).

Firth’s Penalised Likelihood Logistic Regression was used to assess for association between a combination of biomarkers and LN status (outcome: LN active=1; inactive LN JSLE=0). This approach was preferred to a standard linear logistic regression approach since our dataset was susceptible to the statistical phenomenon known as separation [37], making the effect estimates obtained from a standard logistic regression model susceptible to bias. Firth’s Penalised Regression approach removes this bias.

As the aims of this present study are to assess if the results of the previous UK/US urinary biomarker panel study  ADDIN EN.CITE [4] could be validated within the SA cohort, urinary biomarker values were introduced into Firth’s Penalised Likelihood Logistic Regression models in the same order as in the aforementioned study, so that the results of the current study would be comparable to previous analyses. The first model fitted therefore included AGP and CP, and then LPGDS, TF, VCAM-1 and MCP-1 were then sequentially added into the model with the final model including all six biomarkers. The AUC was calculated for the baseline model and updated each time a biomarker was added to the model. AUC values of 1.0–0.9, 0.9–0.8, 0.8–0.7, 0.7–0.6, 0.6–0.5 were considered excellent, good, fair, poor and fail respectively [38]. Data analysis was carried out using R software version 3.3.3 [39].

Results
Clinical and demographic data
The SA Cohort consisted of 23 JSLE patients and 18 HCs (see Table 1). Nine JSLE patients (39%) were classed as having active LN (renal BILAG score A: 8/9; B: 1/9) and 14 (61%) as inactive LN (renal BILAG score D: 5/14; E 9/14), see Table 1. Active LN, inactive LN patients and HCs had a median age of 13.0 [11.4-15.2], 13.9 [12.8-15.1] and 11.0 [10.0-12.0] years respectively, with a disease duration of 2.8 [0.7-4.9] and 2.6 [1.8-4.0] years for active and inactive LN patients respectively at the time of biomarker analysis. 89% (8/9) of the active LN, 86% (12/14) of the inactive LN patients and 78% (14/18) of the HCs were female. SA JSLE patients were mainly Coloured (active LN: 55%; inactive LN: 57%) or Black African (active LN: 34%; inactive LN: 35%). 11% of active LN and 8% of inactive LN patients were Asian. Of the HCs, 45% were Coloured and 55% were Black African. All active LN patients had biopsy proven LN during their disease course, with the ISN/RPS 2003 classes as follows: class III (44%), class IV (34%), and class V (22%), and a median of 6 ACR classification criteria at diagnosis. Active and inactive LN patients differed significantly in terms of their urinary albumin creatinine ratio (UACR, pc<0.01, see Table 1).

Individual novel urinary biomarkers
Figure 1 and Table 2 show the distribution of novel urinary biomarker concentrations in the SA Cohort patients. Patients with active LN had significantly higher urinary concentrations of AGP, CP, LPGDS, TF and VCAM-1 than inactive LN patients (all pc<0.05). MCP-1 levels did not differ between active and in-active LN patients (pc = 0.08). No urine biomarker levels differed significantly between inactive LN and HC patients (all pc values 1.0). The distribution of novel urine biomarker concentrations in active and inactive LN patients, sub-divided according to their ethnic group is shown in supplemental Figure 1. 

Combinations of urinary biomarkers
Including AGP and CP within a logistic regression model provided an AUC of 0.992. Consistent with the previous study  ADDIN EN.CITE [4], the AUC improved when up to four biomarkers were combined with the optimal combination of biomarkers identified as AGP, CP, LPGDS and TF (AUC = 1.0, see Table 3).

Discussion
The main aim of this study was to evaluate whether the optimal urinary biomarker panel for LN identification developed amongst children from the UK JSLE Cohort study and the US Einstein Lupus Cohort  ADDIN EN.CITE [4] displayed the same excellent ability for active LN identification in patients from the SA Paediatric Lupus Cohort study. In all three cohorts (UK, US, and SA) the optimal urinary biomarker combination for active LN identification included AGP, CP, LPGDS and TF with excellent AUC values of 0.920 in the UK, 0.991 in the US  ADDIN EN.CITE [4] and an AUC of 1.0 within the SA Cohort. Such validation of biomarkers within independent racially and geographically distinct patient cohorts is crucial to identifying robust urinary biomarkers meriting translation into clinical practice. 

Assessment within the SA Cohort is complementary to the previous study including UK and US cohort patients given the marked differences in race and LN severity between the patient cohorts. Significant differences in disease phenotype, clinical outcomes, complications, mortality and renal-specific survival rates have been shown to occur in JSLE patients of different ethnicities  ADDIN EN.CITE [23, 27-31, 33, 40, 41]. The SA Cohort comprised of predominately Coloured (57%) and Black African (35%) patients whereas the UK JSLE Cohort included mostly Caucasian (41%) and Indian patients (23%). Within the US Cohort, a majority of African American (53%) and Hispanic patients (43%) were included. In the SA and US Cohorts there was a greater proportion of active LN patients, relative to the total patient numbers (39 and 53% in the SA and US cohorts respectively, compared to 25% in UK). Previously published urinary biomarker panel studies in JSLE have failed to undertake such cross-cohort validation.

The SA Cohort displays a severe LN phenotype, with significantly more SA Cohort patients requiring dialysis and renal transplantation than their North American peers  ADDIN EN.CITE [26]. Within the UK JSLE Cohort Study, up to 80% of patients have been shown to have some degree of renal involvement when followed over a 4.5-year period. However, only 4% of patients displayed persistent Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index renal damage  ADDIN EN.CITE [1], suggestive of a milder LN phenotype within the UK Cohort. The increased LN severity and smaller patient numbers within the SA Cohort may in part explain the AUC of 1.0 for the urinary biomarker panel demonstrated within the current study. 

AGP, CP, LPGDS, TF, albumin, and albumin-related fragments have previously been shown to be significantly higher in BILAG or SLE disease activity index (SLEDAI) defined active versus inactive LN patients, with their combined AUC being 0.85  ADDIN EN.CITE [21]. Biomarker combinations differentiating biopsy defined activity, chronicity or membranous LN in 28 JSLE and 48 adult SLE patients in urine samples taken within 2 months of biopsy demonstrated the best predictive ability for active LN when AGP, MCP-1, CP and protein:creatinine ratio were combined (AUC again 0.85)  ADDIN EN.CITE [42]. Within the SA Cohort included in the current study and UK / US JSLE cohort included in our previous studies, stronger AUC values were therefore demonstrated for identification of active LN (AUCs of 1.0, 0.920 and 0.991 respectively)  ADDIN EN.CITE [4]. Collectively these results support the importance of a combination, urinary biomarker panel approach in LN. 

Importantly, in this study, patients were considered to have active LN on the basis of their renal BILAG score and having a previous renal biopsy demonstrating active LN. This led to the following limitations; firstly, as the composite renal BILAG score is calculated from proteinuria, GFR, blood pressure, active urine sediment, plasma creatinine and recent biopsy findings, we could not directly compare such traditional markers with the novel urinary biomarkers studied. Secondly, other research groups have previously used other indices of renal disease activity (e.g. SLEDAI, biopsy)  ADDIN EN.CITE [21, 22, 42], influencing the ability to directly compare results between different studies. The composite renal BILAG scoring system provides the most comprehensive assessment of renal activity  ADDIN EN.CITE [43, 44] and was therefore included in the current study. Future work including urine samples collected at the time of renal biopsy would enable head to head comparison of urine and traditional renal biomarkers. 

This is the first study to date to investigate urine biomarkers in paediatric LN patients from Sub-Saharan Africa. The cross-sectional nature of this study and relatively small number of patients do however limit our ability to comment on the relationship of such novel urinary biomarkers with different stages of the fluctuating LN disease course (e.g. prediction of flare, remission, response to treatment and chronic damage), and to draw clear conclusions regarding the influence of ethnic sub-groups on urine biomarker levels (see Supplemental Figure 1). It would also be interesting to know in patients with persistent active or inactive LN, how much the urine biomarker panel fluctuates over time. Within this study we used a more specialist and conservative statistical modelling approach) than in our previous study  ADDIN EN.CITE [4] (Firth’s Penalised Likelihood Logistic Regression modelling), to prevent overfitting of the model given the smaller sample size. In the current cohort, urinary MCP-1 levels did not differ between active and inactive LN patients (pc = 0.08), and this may be a reflection of the sample size and statistical techniques, therefore further assessment in a bigger group of patients is warranted. Future validation of the urinary biomarker panel in a larger, longitudinal, prospectively collected study is therefore the next step to advance this biomarker panel towards translation into clinical practice. Ultimately it is hoped that development of a point of care test, providing rapid results in the clinic or patients home could help to improve renal outcomes and reduce costs associated with renal biopsies [45], and in-patient treatments.

Conclusions
This study provides further validation of the excellent novel urinary biomarker panel comprised of AGP, CP, LPGDS and TF for identification of active LN, within a SA Paediatric Lupus Cohort. This is the first study to look at urinary biomarkers in an African JSLE population, highlighting the importance of including this population and adding considerable strength to the original UK and US JSLE cohort findings  ADDIN EN.CITE [4]. The SA Cohort displays a relatively severe LN phenotype compared with previous studies  ADDIN EN.CITE [26], suggesting that the biomarker panel performs extremely well despite racial diversity within the cohort (Coloured, Black African and Asian patients included) and a wide range of disease severity. Further prospective, longitudinal validation is required to define biomarker profiles that predict LN relapses, remission, treatment response and chronic damage. Future development of an assay to simultaneously measure all markers would help to streamline the process of biomarker quantification, reduce costs and increase its clinical utility. 
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	Active LN(n=9)	Inactive LN(n=14)	HCs(n=18)	pc
Agea	13.0 [11.4-15.2]	13.9 [12.8-15.1]	11.0 [10.1-12.0]	ns
Durationb	2.8 [0.7-4.9]	2.6 [1.8-4.0]	NA	ns
Female	8 (89)	12 (86)	14 (78)	ns
ACRc	6 [4-8]	5 [4-6]	NA	ns
PrednisolonedMMFeCYCf everRituxg everACEi / AT2h	6 (67)3 (33)1 (11)1 (11)5 (56)	8 (57)7 (50)001 (7)	NA	ns
GFRi	136 [72-156]	150 [118-160]	NA	ns
UACRj	210 [90-415]	15 [10-20]	NA	<0.01
Serum creatininek	39 [36-78]	40 [35-51]	NA	ns
dsDNAl	48 [12-244]	17 [9-42]	NA	ns
C3m	1.0 [0.7-1.1]	1.2 [0.9-1.3]	NA	ns
ESRn	61 [25-83]	50 [20-77]	NA	ns
Colouredo	5 (55)	8 (57)	8 (45)	ns
Black African	3 (34)	5 (35)	10 (55)	ns
Asian	1 (11)	1 (8)	0	ns
Table 1: Clinical, demographic, and laboratory measurements of patients and HCs at the time of urinary biomarker quantification. 
Data expressed as median values and interquartile ranges in square brackets, or numbers and percentages in curved brackets. p-values are Bonferroni-corrected (pc) from Chi Squared tests, Mann-Whitney U or Kruskall-Wallis tests as appropriate depending on the number of comparisons, ns = pc>0.05, NA = not applicable as comparing with HCs who have not had the laboratory measurements mentioned. aAge in years at time of analysis. bDuration = disease duration in years. cACR = number of American College of Rheumatology criteria for SLE fulfilled at diagnosis. dCurrent medication use described for regular medications, those taken in courses / intermittently are described as having been used ‘ever’. eMMF= mycophenolate mofetil. fCYC = cyclophosphamide. gRitux = rituximab. hACEi / AT2= angiotensin converting enzyme inhibitor or angiotensin 2 blocker. iGFR = glomerular filtration rate, jUACR = urinary albumin creatinine ratio (mg/mmolCr), kserum creatinine (mol/L). ldsDNA = anti-double stranded DNA antibody (IU/L), mC3 = complement factor 3 (g/L), nESR = erythrocyte sedimentation rate (mm/h). oColoured is an label for people of mixed ethnic origin who possess ancestry from Europe, Asia, and various Khoisan and Bantu ethnic groups of southern Africa.



	Active LN	Inactive LN	HCa	Actb vs. inactc (pc)d	Inact vs. HC (pc)
AGP(ngmgCr)	145,435[54,746-250,367]	680[394-2,985]	605 [408-1,458]	<0.001	1.0
CP(ngmgCr)	51,714[34,861-177,503]	1,901[1,140-3,276]	1,700 [1,324-2,999]	<0.001	1.0
LPGDS (ngmgCr)	2,683[1,640-3,602]	601[151-900]	577 [314-765]	0.018	1.0
TF(ngmgCr)	63,630[38,071-156,026]	433[221-1,020]	425[234-928]	<0.001	1.0
MCP-1(pgmgCr)	1,020[410-3,642]	219[150-334]	296[186-448]	0.080	1.0
VCAM-1(ngmgCr)	58.8[41.9-119]	4.3[1.9-11.4]	4.0 [2.3-5.9]	0.010	1.0
Table 2: Urine biomarker concentrations standardised to urinary creatinine in active, inactive LN and HC SA Cohort patients.
aHC = healthy controls. bAct = active LN. cInact = inactive LN. dBonferroni corrected p-values (pc) shown. Median and interquartile range biomarker values provided. Mann Whitney U tests used to compare distribution of biomarker concentrations between patient groups.




Biomarker combinations included in the binary logistic regression models	AUCa
AGP + CP	0.992 (0.970,1)
AGP + CP + LPGDS	0.992 (0.970,1)
AGP + CP + LPGDS + TF	1 (1,1)
AGP + CP + LPGDS + TF + VCAM-1	NAb
AGP + CP + LPGDS + TF + VCAM-1 + MCP-1	NA
Table 3: Effect on AUC of combining biomarkers within binary regression models.
Biomarkers were combined in the same order as in the previous urinary biomarker panel study  ADDIN EN.CITE [4]. aAUC = area under the curve with the 95% confidence intervals in curved brackets. bIt was not possible to fit the models including VCAM-1 and MCP-1 due to patient numbers.



Figure 1: Distribution of biomarker concentrations in active / inactive LN patients and HCs. 
Median biomarker values shown by middle horizontal line. Upper line shows 75th percentile and lower line shows the 25th percentile. Mann-Whitney U tests used to compare distribution of biomarker concentrations between active vs. inactive, and inactive vs. HC patient groups. Bonferroni corrected p-values (pc) shown. 

Supplemental Figure 1: Distribution of biomarker concentrations in active / inactive LN patients according to ethnic group. 
Median biomarker values shown by middle horizontal line. Upper line shows 75th percentile and lower line shows the 25th percentile. None of the active LN patients were Caucasian. 









